These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 37200978)

  • 1. The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease.
    Finney AC; Das S; Kumar D; McKinney MP; Cai B; Yurdagul A; Rom O
    Front Cardiovasc Med; 2023; 10():1116861. PubMed ID: 37200978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease.
    Park JH; Koo BK; Kim W; Kim WH;
    Hepatol Int; 2021 Oct; 15(5):1148-1159. PubMed ID: 34081289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.
    Negi CK; Babica P; Bajard L; Bienertova-Vasku J; Tarantino G
    Metabolism; 2022 Jan; 126():154925. PubMed ID: 34740573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Soejima Y; Fukusato T
    World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases.
    Zhang D; Mi Z; Peng J; Yang T; Han Y; Zhai Y; Song C; Teng X; Sun W; Guo J; Bilonda KP
    J Cardiovasc Pharmacol; 2023 May; 81(5):327-335. PubMed ID: 36917556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?
    Choudhary NS; Duseja A
    J Clin Exp Hepatol; 2019; 9(4):506-514. PubMed ID: 31516267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drugs for NAFLD: lessons from basic models to the clinic.
    Reimer KC; Wree A; Roderburg C; Tacke F
    Hepatol Int; 2020 Jan; 14(1):8-23. PubMed ID: 31802390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.
    Muzurović E; Peng CC; Belanger MJ; Sanoudou D; Mikhailidis DP; Mantzoros CS
    Hypertension; 2022 Jul; 79(7):1319-1326. PubMed ID: 35465684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk.
    Alkhouri N; Tamimi TA; Yerian L; Lopez R; Zein NN; Feldstein AE
    Dig Dis Sci; 2010 Sep; 55(9):2644-50. PubMed ID: 19960252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
    Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
    Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
    Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.
    Siddiqui MS; Fuchs M; Idowu MO; Luketic VA; Boyett S; Sargeant C; Stravitz RT; Puri P; Matherly S; Sterling RK; Contos M; Sanyal AJ
    Clin Gastroenterol Hepatol; 2015 May; 13(5):1000-8.e3. PubMed ID: 25311381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology.
    Yoon IC; Eun JR
    Yeungnam Univ J Med; 2019 May; 36(2):67-77. PubMed ID: 31620616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis.
    Esteban JPG; Asgharpour A
    Gastroenterol Clin North Am; 2020 Mar; 49(1):105-121. PubMed ID: 32033758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic steatohepatitis: global impact and clinical consequences.
    Kabarra K; Golabi P; Younossi ZM
    Endocr Connect; 2021 Oct; 10(10):R240-R247. PubMed ID: 34486981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
    Caussy C; Reeder SB; Sirlin CB; Loomba R
    Hepatology; 2018 Aug; 68(2):763-772. PubMed ID: 29356032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.